InsidersTradesSigma
Oncoinvent ASA Stock: price and directors' dealings · Norway · Oslo Børs
Track the Oncoinvent ASA share price and the full management transaction log of the company, a publicly traded company based in Norway. Shares are listed on NO NO, under the oversight of Oslo Børs. Operating in the Health Care sector, Oncoinvent ASA has logged 29 public disclosures. The latest transaction was disclosed on 20 May 2026 (Purchase). Among the most active insiders: Martin Olin. The full history is free.
29
Insider Decl.
0
Thresholds
€102,959
13 ops.
Buy Volume
€96,655
4 ops.
Sell Volume
10Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 20 May 2026
Declarations29 total
OptionXOSLOSLO:674043
Ideal exit: 14 Feb 2027 (T+270)
OptionXOSLOSLO:663505
OptionXOSLOSLO:662758
@ €0.0425ShareXOSLOSLO:661415
ShareXOSLOSLO:661083
ShareXOSLOSLO:660766
OptionXOSLOSLO:659775
OptionXOSLOSLO:659736
ShareXOSLOSLO:658546
ShareXOSLOSLO:615795
2,940,000 shares@ NOK 0.170544.7% of flowShareXOSLOSLO:615250
OptionXOSLOSLO:606114
ShareXOSLOSLO:604595
314,826 shares@ NOK 0.10100.0% of flowShareXOSLOSLO:593289
ShareXOSLOSLO:593079
ShareXOSLOSLO:592857
2,950 sharesShareXOSLOSLO:592707
XOSLOSLO:591924
Ideal exit: 23 Feb 2024 (T+270)
2,117,900 shares@ NOK 0.297555.3% of flowShareXOSLOSLO:591546
25,000 shares@ NOK 10.73100.0% of flowShareXOSLOSLO:565094
Ideal exit: 13 Mar 2023 (T+270)
9,100 shares@ NOK 20.5124.9% of flowShareXOSLOSLO:551082
Ideal exit: 7 Oct 2022 (T+270)
10,000 shares@ NOK 20.4327.2% of flowShareXOSLOSLO:550973
Ideal exit: 4 Oct 2022 (T+270)
10,000 shares@ NOK 20.0326.7% of flowShareXOSLOSLO:550930
Ideal exit: 4 Oct 2022 (T+270)
8,000 shares@ NOK 19.8721.2% of flowShareXOSLOSLO:550844
Ideal exit: 3 Oct 2022 (T+270)
25 of 29 declarations
About Oncoinvent ASA
Oncoinvent ASA is a Norwegian company focused on developing innovative cancer treatments. It is listed on the Oslo Stock Exchange (XOSL).
